Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Teva Pharmaceutical Industries Ltd. Meets Earnings Targets Despite a Mild European Winter

Image source: Teva.

Pharmaceutical specialist Teva (NYSE: TEVA  ) just announced results for the first quarter of 2014.

Sales increased 2% year over year to $5 billion, falling short of the $5.1 billion analyst consensus. Teva's earnings increased 8% to $1.22 per share and American Depositary Receipt, matching Wall Street's expectations.

The generics segment reported 3% year-over-year sales growth, accounting for 46% of Teva's total revenue. The segment was helped by the release of new medications in Europe and North America, but hindered by a mild European winter and increased competition in America.

In the specialty segment, sales increased by 3%. The gain was driven by more than 20% growth in Parkinson's disease treatment Azilect, narcolepsy medication Nuvigil, and asthma inhalator drug ProAir.

The over-the-counter division saw sales of $269 million, a 12% decrease from the year-ago period. This drop was driven by "an exceptionally weak cough and cold season in Europe and Russia," according to Teva.

The Israel-based company launched a modified version of its blockbuster Copaxone multiple sclerosis medication during the quarter. About one-third of all Copaxone patients in America have already switched to the new thrice-a-week dosing schedule.

"We are intensely focused on solidifying the foundation of Teva, maintaining the Copaxone franchise, driving sustainable organic growth, and positioning Teva for long-term value creation," said CEO Erez Vigodman in a prepared statement.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2938805, ~/Articles/ArticleHandler.aspx, 9/1/2015 10:13:52 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Anders Bylund

Anders Bylund is a Foolish Technology and Entertainment Specialist. Where the two markets intersect, you'll find his wheelhouse. He has been an official Fool since 2006 but a jester all his life.

Hypoallergenic. Contains six flavors not found in nature. Believes in coyotes and time as an abstract.

Follow Anders on Twitter, LinkedIn, and Google+.

Today's Market

updated Moments ago Sponsored by:
DOW 16,196.57 -331.46 -2.01%
S&P 500 1,930.69 -41.49 -2.10%
NASD 4,700.97 -75.54 -1.58%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 9:57 AM
TEVA $63.28 Down -1.13 -1.75%
Teva Pharmaceutica… CAPS Rating: ****